TY - JOUR T1 - Safety and Efficacy of RAD001 (Everolimus) Administered Upon Relapse During or After Adjuvant Treatment in Post-menopausal Women With Hormone Receptor Positive, HER2/neu Negative Locally Advanced or Metastatic Breast Cancer (CRAD001JGR08 “MELPOMENI” study) JF - Anticancer Research JO - Anticancer Res SP - 1031 LP - 1041 DO - 10.21873/anticanres.15564 VL - 42 IS - 2 AU - ATHANASIOS ALEXOPOULOS AU - CHARISIOS KARANIKIOTIS AU - ALEXANDROS ARDAVANIS AU - IOANNIS BOUKOVINAS AU - PARISIOS MAKRANTONAKIS AU - CHRISTOS PAPADIMITRIOU AU - ATHANASIOS ATHANASIADIS AU - ANASTASIOS BOUTIS AU - STYLIANOS GIASSAS AU - STYLIANOS KAKOLYRIS AU - GEORGIOS KOUMAKIS AU - KONSTANTINOS PAPAZISIS AU - ADAMANTIA PSYRRI AU - NIKOLAOS ZIRAS AU - SOFIA BAKA AU - NIKOLAOS KENTEPOZIDIS AU - VASILIKI MICHALAKI Y1 - 2022/02/01 UR - http://ar.iiarjournals.org/content/42/2/1031.abstract N2 - Background/Aim: This study aimed to provide real-world safety and effectiveness data of everolimus (EVE) plus exemestane (EXE) in estrogen receptor positive/human epidermal growth factor receptor 2 negative (ER+/HER2–) advanced breast cancer (aBC). Patients and Methods: This prospective observational study was conducted by 19 hospital-based oncologists in Greece. Eligible patients were treated with EVE+EXE in the first-line setting; EVE was initiated according to the approved label. Results: Overall, 75 eligible patients (mean age: 66.9 years; visceral metastases: 49.3%; bone-only metastases: 37.3%) were included in the effectiveness analyses. Over a median (interquartile range) of 12.1 months (range=4.2-20.5 months) of EVE treatment, the median progression-free survival was 18.0 months and the overall response rate was 22.7%. Among patients that received ≥1 EVE dose (n=80), the incidence of EVE-related adverse events was 72.5% (serious: 55.0%); stomatitis (22.5%), fatigue (22.5%), pneumonitis (18.8%); and cough (18.8%) were the most common. Conclusion: In the routine care in Greece, EVE demonstrates clinical benefit and a predictable safety profile. ER -